11 Best Emerging Technology Stocks to Buy Right Now

Page 7 of 10

4. Beam Therapeutics Inc. (NASDAQ:BEAM)

Focus Area: Gene editing via base editing

Market Cap: $2.1 Billion

Potential Upside: 106%

Number of Hedge Fund Holders: 31

Beam Therapeutics Inc. (NASDAQ:BEAM) is one of the best emerging technology stocks to buy right now. The company develops precision genetic medicines using base editing, a next-generation approach that makes single-letter changes in DNA without cutting the double helix.

This innovation reduces risks associated with traditional gene editing and offers higher accuracy. Beam’s platform could become the standard for safe and precise genetic corrections, placing it firmly among emerging biotech leaders.

On September 15, Patrick Trucchio from H.C. Wainwright maintained his Buy rating on Beam Therapeutics Inc. (NASDAQ:BEAM), keeping his price target of $80 unchanged. The analyst based his positive stance on the company’s steady progress across its base editing pipeline, both ex vivo and in vivo.

The analyst highlighted several products in the pipeline to make his case. He said Beam Therapeutics Inc.’s (NASDAQ:BEAM) lead program, BEAM-101, is advancing as a registrational candidate for sickle cell disease and could move toward a BLA filing in the near term. Alongside this, BEAM-302 is in dose expansion studies for alpha-1 antitrypsin deficiency and has been drawing strong investor interest. Early data suggest it could be a best-in-class therapy, showing meaningful biochemical improvements, with ongoing work focused on dose optimization.

Trucchio noted that while BEAM-302 has emerged as a potential star program, the sickle cell franchise anchored by BEAM-101 remains central to Beam’s strategy.

Beam Therapeutics Inc. (NASDAQ: BEAM) is a biotechnology company that develops precision genetic medicines using base editing technologies for the treatment of various diseases.

Page 7 of 10